PATENT CLAIM ANALYSIS

Application Number: 15985106
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "171000"]

Abstract:
A novel combination comprising a 17 α-hydroxylase/C17,20 lyase inhibitor, for example: (3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol or a pharmaceutically acceptable salt or ester thereof, and an AKT inhibitor, for example: N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of 17 α-hydroxylase/C17,20 lyase and/or AKT inhibition is beneficial, e.g., cancer.

Claim (Index 14):
A combination according to  claim 1  where the amount of the compound of Structure (I) is an amount selected from 750 mg to 1,250 mg, and that amount is suitable for administration once per day in one or more tablets, and the amount of the compound of Structure (II) is an amount selected from 50 mg to 300 mg, and that amount is suitable for administration once per day.

Metadata:
- Claim Count in Document: 28.0
- Percentile: 93.0
- Lexical Diversity: 1.62121
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15385205', '13500698', '13991576', '13699077', '14456180']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7646038513572941
- 35 USC 102 Novelty (BERT): 0.5124633039212836
- Combined Prediction Score: 0.7393897966136931
- Mean Citation Score: 263.49821000000003
- Max Citation Score: 288.44916
- Similarity Product: 212.3436104031801

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test